NCT03425643
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 31, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
The 49 most recent of 161 versions: 48 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial completed
- Minor Study completion pushed from Jun 29, 2026 to Oct 15, 2026v161
- Minor Publications: details revised at 1 of 6 entriesv160
- Notable Results first posted: Sep 19, 2024
- Secondary endpoints: details revised at 2 of 7 entries
- Minor Secondary endpoints: details revised at 2 of 7 entriesv158
Show 44 earlier versionsHide 44 earlier versions
- Minor Secondary endpoints: 6 to 7v157
- Minor Enrollment target: estimated 786 to confirmed 797
- Primary completion date changed from estimate of Jan 20, 2024 to Jul 10, 2023
- Minor Publications: details revised at 1 of 6 entriesv155
- Notable Eligibility criteria shortened, about 35 wordsv154
- Notable Eligibility criteria shortened, about 15 wordsv152
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 227 of 227 sites
- Minor Site details revised at 3 of 227 sitesv150
- Minor Site details revised at 2 of 227 sitesv149
- Minor Site details revised at 4 of 227 sitesv148
- Minor Study sites revised (227)v147
- Minor Site details revised at 1 of 227 sitesv146
- Minor Site details revised at 4 of 227 sitesv145
- Minor Site details revised at 2 of 227 sitesv144
- Minor Study sites revised (227)v143
- Minor Site details revised at 8 of 227 sitesv142
- Minor Site details revised at 7 of 227 sitesv141
- Minor Study sites: 226 to 227v140
- Minor Site details revised at 1 of 226 sitesv139
- Minor Site details revised at 1 of 226 sitesv138
- Minor Study sites: 225 to 226v137
- Minor Site details revised at 3 of 225 sitesv136
- Minor Site details revised at 4 of 225 sitesv135
- Notable Eligibility criteria revised
- Secondary endpoints: details revised at 6 of 6 entries
- Site details revised at 7 of 225 sites
- Minor Site details revised at 1 of 225 sitesv133
- Minor Site details revised at 2 of 225 sitesv132
- Minor Study sites: 226 to 225v131
- Minor Site details revised at 4 of 226 sitesv130
- Minor Site details revised at 1 of 226 sitesv129
- Minor Site details revised at 2 of 226 sitesv128
- Minor Site details revised at 3 of 226 sitesv127
- Minor Site details revised at 1 of 226 sitesv126
- Minor Study sites: 225 to 226v125
- Minor Site details revised at 2 of 225 sitesv124
- Minor Site details revised at 3 of 225 sitesv123
- Minor Study sites: 224 to 225v122
- Minor Study sites: 222 to 224v121
- Minor Site details revised at 2 of 222 sitesv120
- Minor Study sites: 216 to 222v119
- Minor Study sites: 215 to 216v118
- Minor Study sites: 214 to 215v117
- Minor Site details revised at 1 of 214 sitesv116
- Minor Study sites: 213 to 214v115
- Minor Study sites: 212 to 213v114
- Minor Study sites: 211 to 212v113
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of pembrolizumab \[200 mg, intravenous (IV); given on cycle day 1\] in combination with platinum doublet neoadjuvant chemotherapy (NAC), consisting of cisplatin \[75 mg/m\^2, IV; given on cycle day 1\] and either Gemcitabine \[1000 mg/m\^2, IV; given on cycle days 1 and 8\] or Pemetrexed \[500 mg/m\^2, IV; given on cycle day 1\]. Adjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of pembrolizumab \[200 mg, IV; given on cycle day 1\].
Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of placebo \[normal saline, IV; given on cycle day 1\] in combination with platinum doublet NAC, consisting of cisplatin \[75 mg/m\^2, IV; given on cycle day 1\] and either Gemcitabine \[1000 mg/m\^2, IV; given on cycle days 1 and 8\] or Pemetrexed \[500 mg/m\^2, IV; given on cycle day 1\]. Adjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of placebo \[normal saline, IV; given on cycle day 1\].
Biologicals: Pembrolizumab
Drugs: Placebo, Cisplatin, Gemcitabine, Pemetrexed
Sites
227 sites in 25 countries
United States 51, China 15, Germany 15, Romania 13, Brazil 12, Japan 12, France 11, Argentina 10, Italy 10, Russia 9, Ukraine 9, Spain 8, United Kingdom 8, Belgium 6, Poland 6, Taiwan 6, Canada 5, South Korea 5, South Africa 4, Ireland 3, Australia 2, Latvia 2, Lithuania 2, Malaysia 2, Estonia 1